微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 33.29% | -16.11% | -7.61% | 110/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 36.03% | -9.08% | -2.86% | 105/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 37.1% | -9.02% | -5.47% | 101/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 39.24% | 2.39% | -1.12% | 104/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 39.69% | 2.08% | 0.14% | 102/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 39.63% | 1.17% | -2.8% | 100/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 40.77% | 0.65% | 6.39% | 92/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 38.33% | 0.65% | -1.42% | 110/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 38.88% | -2.21% | -0.74% | 107/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 39.17% | -3.52% | -3.3% | 106/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 40.51% | -4.96% | 6.38% | 97/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 38.08% | -12.9% | -4.22% | 106/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 39.76% | -10.11% | -2.08% | 99/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 40.6% | -6.62% | -4.74% | 97/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 42.62% | -6.42% | -2.51% | 91/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 43.72% | -7.13% | -1.15% | 92/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 44.23% | -4.65% | 1.72% | 82/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 43.48% | -3.96% | -4.53% | 88/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 45.55% | 3.83% | -3.25% | 75/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 47.08% | -5.24% | 1.48% | 87/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 46.39% | -9.57% | 2.46% | 78/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 45.27% | -11.8% | 3.21% | 86/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 43.87% | -15.73% | -11.7% | 77/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 49.68% | 1.85% | -3.16% | 79/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 51.3% | 2.74% | -0.06% | 60/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 51.33% | 5.35% | -1.39% | 62/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 52.05% | 8.02% | 6.72% | 55/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 48.78% | 12.56% | -2.31% | 75/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 49.93% | 26.99% | 2.48% | 55/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 48.72% | 26.51% | 1.11% | 58/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 48.19% | 22.29% | 11.21% | 58/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 43.33% | 19.87% | 10.21% | 74/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 39.32% | 9.38% | 2.09% | 60/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 38.51% | 6.48% | -2.26% | 67/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 39.41% | 9.57% | 9.01% | 48/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 36.15% | 3.71% | 0.56% | 77/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 35.95% | -25.38% | -0.62% | 51/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 36.17% | -25.12% | 0.58% | 58/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 35.96% | -21.51% | 3.18% | 50/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 34.86% | -24.86% | -27.65% | 70/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 48.17% | 6.36% | -0.28% | 32/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 48.31% | 5.95% | 5.43% | 36/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 45.82% | -2.24% | -1.22% | 34/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |